Preventive effects of pneumococcal and influenza vaccines on community-acquired pneumonia in older individuals in Japan: a case-control study

Human Vaccines & Immunotherapeutics
Kanzo SuzukiYoshio Hirota

Abstract

At present, there are few reports that have clarified the effectiveness of 23-valent pneumococcal polysaccharide vaccine (PPSV23) against all-cause pneumonia or pneumococcal pneumonia in community-acquired pneumonia (CAP) in older individuals in Japan. We conducted a hospital-based matched case-control study to investigate separately the preventive effects of PPSV23 and trivalent influenza vaccine (TIV) on all-cause CAP and pneumococcal CAP in older individuals in Japan. Cases were individuals aged 65 years or older who were newly diagnosed with CAP from October 2010 to September 2014. Two control patients with a different disease (one respiratory medicine and one non-respiratory medicine) matched for sex, age, date of outpatient visit, and medical institution were selected for each case. Odds ratios (ORs) and 95% confidence intervals (CIs) of PPSV23 and TIV for the occurrence of all-cause CAP and pneumococcal CAP were calculated using conditional and unconditional logistic regression models. The analysis included 161 cases and 308 controls from the 4-year period. The adjusted OR for the occurrence of all-cause CAP was 0.76 (95%CI = 0.44-1.32) with PPSV23 vaccination and 0.79 (95%CI = 0.50-1.25) with TIV vaccination compared wi...Continue Reading

References

Jun 1, 1983·Proceedings of the Society for Experimental Biology and Medicine·M A MufsonG Schiffman
Jan 10, 2003·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Toshiharu Matsushima
Apr 7, 2004·The European Respiratory Journal·B ChristensonA Ortqvist
Aug 31, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Angel Vila-CórcolesUNKNOWN EVAN Study Group
Mar 5, 2008·Journal of the American Geriatrics Society·Shinji TeramotoUNKNOWN Japanese Study Group on Aspiration Pulmonary Disease
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Oct 5, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ivan F N HungKwok-Yung Yuen
Mar 19, 2013·Vaccine·Michael L Jackson, Jennifer C Nelson
Feb 18, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Olga Ochoa-GondarImma Hospital-Guardiola
Feb 7, 2015·Geriatrics & Gerontology International·Masakazu WashioUNKNOWN Kyushu Task Force for CAP Risk in the Elderly
Feb 14, 2015·Journal of Hospital Medicine : an Official Publication of the Society of Hospital Medicine·Chenghui LiGuoqing J Chen
Mar 31, 2015·PloS One·Konosuke MorimotoUNKNOWN Adult Pneumonia Study Group-Japan (APSG-J)
Apr 23, 2015·Human Vaccines & Immunotherapeutics·Kyoko KondoUNKNOWN Pneumonia in Elderly People Study Group
Oct 21, 2015·Emerging Infectious Diseases·Kimiko UbukataUNKNOWN Invasive Pneumococcal Diseases Surveillance Study Group

❮ Previous
Next ❯

Citations

Jan 21, 2021·Current Opinion in Infectious Diseases·Christian Davis FurmanForest W Arnold
Mar 12, 2021·Scientific Reports·Kyoko KondoUNKNOWN Pneumonia in Elderly People Study Group

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Software Mentioned

SAS

Related Concepts

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.